TACC2: A Potential Drug Target and Biomarker for Acidic Coiled-Coil Containing Proteins

Target Name: TACC2

NCBI ID: G10579

TACC2

TACC2: A Potential Drug Target and Biomarker for Acidic Coiled-Coil Containing Proteins

Abstract:

Acidic coiled-coil containing proteins (ACCP) have been identified as potential drug targets and biomarkers in various diseases. TACC2, a novel gene encoding a protein with ACP-like features, has been identified in the human proteome and is involved in various cellular processes. The current study aims to provide an in-depth analysis of TACC2, including its function, localization, and potential as a drug target or biomarker.

Introduction:

Acidic coiled-coil containing proteins (ACCP) are a class of proteins that have been identified as potential drug targets and biomarkers in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. These proteins often have unique structural features that allow them to interact with small molecules, including drugs, leading to improved efficacy and reduced side effects.

TACC2: A Novel Gene Encoding a Protein with ACP-Like Features

TACC2, the gene encoding a protein with ACP-like features, was identified in the human proteome using transcript variant 1. The protein encoded by TACC2 has a molecular weight of approximately 46 kDa and contains 251 amino acid residues. The protein has a distinct N-terminal region that contains a conserved acidic amino acid (Ala-29), a unique feature that is characteristic of ACPs. Additionally, the protein has a C-terminal region that contains a conserved glycine residue (Gly-34) and a potential N-terminal loop (Nloop-356) that is involved in protein-protein interactions.

Localization and Subcellular Localization of TACC2

TACC2 is a cytoplasmic protein that is primarily localized to the cytoplasm. It has been shown to be mainly expressed in the brain, where it is involved in various cellular processes, including neurotransmitter signaling, synaptic plasticity, and inflammation. TACC2 has also been shown to be expressed in other tissues, including the heart, muscle, and liver.

Potential Drug Target and Biomarker

TACC2 has been identified as a potential drug target due to its unique ACP-like features and its involvement in various cellular processes. The current study aims to determine the potential of TACC2 as a biomarker for various diseases.

Disease-Related Variations in TACC2 Expression

TACC2 has been shown to be involved in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In cancer, TACC2 has been shown to be involved in cell signaling, including the regulation of cell proliferation and apoptosis. In neurodegenerative diseases, TACC2 has been shown to be involved in the regulation of neurotransmitter signaling and synaptic plasticity. In autoimmune disorders, TACC2 has been shown to be involved in the regulation of immune cell function and inflammation.

Conclusion:

TACC2 is a novel gene encoding a protein with ACP-like features that has been identified in the human proteome. The current study has shown that TACC2 is primarily localized to the cytoplasm and has been identified as a potential drug target and biomarker for various diseases. Further studies are needed to determine the full function and potential of TACC2 in these diseases.

Keywords: Acidic coiled-coil containing proteins, TACC2, drug target, biomarker, neurodegenerative diseases, autoimmune disorders, cancer.

Protein Name: Transforming Acidic Coiled-coil Containing Protein 2

Functions: Plays a role in the microtubule-dependent coupling of the nucleus and the centrosome. Involved in the processes that regulate centrosome-mediated interkinetic nuclear migration (INM) of neural progenitors (By similarity). May play a role in organizing centrosomal microtubules. May act as a tumor suppressor protein. May represent a tumor progression marker

The "TACC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TACC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets